三生制药（01530.HK）今日盘中大涨14.90%，截至上午9:30，报16.66港元。该股价的大幅上涨主要源于公司与辉瑞达成的一项重大许可协议。
根据公告，三生制药及其子公司将向辉瑞授予自主研发的PD-1/VEGF双特异性抗体SSGJ-707在全球（不包括中国内地）的独家开发、生产和商业化权利。作为回报，三生制药将获得12.5亿美元的首付款，以及最高可达48亿美元的潜在里程碑付款。此外，三生制药还将获得授权地区产品净销售额的双位数百分比特许权使用费。
这项合作不仅为三生制药带来可观的财务回报，更标志着公司在国际化进程中取得重大突破。SSGJ-707已获得中国突破性疗法认定资格，并在非小细胞肺癌等多个适应症的临床试验中展现出优异的效果。市场对这一合作反应积极，认为这将显著提升三生制药在全球生物医药产业链中的地位，推动公司加速实现打造世界级生物制药企业的战略目标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.